Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal junction cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.10.19
Views: 249
Rating:

Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain

Dr Maria Alsina speaks to ecancer at ESMO 2019 in Barcelona about quality of life results from the KEYNOTE-062 study.

The study looked at pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced gastric or gastroesophageal junction cancer.

Dr Alsina says the study demonstrated that giving the patients pembrolizumab is not inferior to giving them the standard chemotherapy with regards to quality of life. 

 

Related videos

follow us

Oncology knowledge


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation